



**Mr. Rajendra Nehete**  
**Vice President, Quality**

Sterling Healthcare Limited  
Gat No 396, Village Urse, Near Talegaon Toll Plaza,  
Mumbai – Pune Expressway, Maval, Pune, Maharashtra  
410 506, India

**Ref:** OGYÉI/60942-6/2016  
**Subject:** GMP Certificate  
**Date:** 21 April 2017

Dear Mr. Rajendra Nehete,

Please find attached the GMP certificate of your facility registered in EudraGMDP database.

Sterling Healthcare Limited  
Gat No 396, Village Urse, Near Talegaon Toll Plaza, Mumbai – Pune Expressway,  
Maval, Pune, Maharashtra 410 506, India

Please consider that the changes related to the GMP system are to be reported on yearly basis.  
You are also requested to report the authorisation of a medicinal product in the EU and any event which affects the GMP compliance.

Yours sincerely,

  
Dr. Szilárd Nagy  
Deputy General Director





*National Institute of Pharmacy and Nutrition*

CERTIFICATE NUMBER: *OGYÉI/60942/2016*

**CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER**<sup>1, 2</sup>

**Part 1**

Issued following an inspection in accordance with :  
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Hungary confirms the following:

The manufacturer: *Sterling Healthcare Ltd.*

Site address: *GAT No. 396, Village Urse, Near Talegaon Toll Plaza, Mumbai-Pune Expressway, Maval, Pune, Maharashtra, 410506, India*

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 19(3) of Regulation 726/2004/EC .

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on *2017-03-11* , it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC<sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

<sup>1</sup> The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

<sup>2</sup> Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>3</sup> These requirements fulfil the GMP recommendations of WHO.

## Part 2


Human Medicinal Products

### 1 MANUFACTURING OPERATIONS

<b>1.2</b>	<b>Non-sterile products</b>
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.1 Capsules, hard shell 1.2.1.13 Tablets
<b>1.5</b>	<b>Packaging</b>
	<i>1.5.1 Primary Packing</i> 1.5.1.1 Capsules, hard shell 1.5.1.13 Tablets
	<i>1.5.2 Secondary packing</i>
<b>1.6</b>	<b>Quality control testing</b>
	1.6.2 <i>Microbiological: non-sterility</i> 1.6.3 <i>Chemical/Physical</i>

2017-04-21

Name and signature of the authorised person of the  
Competent Authority of Hungary



-----

**Mr. Szilard Nagy**  
**National Institute of Pharmacy and Nutrition**  
Tel: +36 1886 9305  
Fax: +36 1886 9461